A First-in-human, Dose-escalation Study of the Methionine Aminopeptidase 2 Inhibitor M8891 in Patients with Advanced Solid Tumors.

Carducci, Michael A; Wang, Ding; Habermehl, Christina; Bödding, Matthias; Rohdich, Felix; Lignet, Floriane; Duecker, Klaus; Karpenko, Oleksandr; Pudelko, Linda; Gimmi, Claude; LoRusso, Patricia

Carducci, Michael A; Wang, Ding; Habermehl, Christina; Bödding, Matthias; Rohdich, Felix; Lignet, Floriane; Duecker, Klaus; Karpenko, Oleksandr; Pudelko, Linda; Gimmi, Claude; LoRusso, Patricia.

Affiliation

Carducci MA; Oncology and Urology, Hopkins Kimmel Cancer Center, Baltimore, Maryland.
Wang D; Phase 1 Clinical Trials Program, Henry Ford Cancer Institute, Detroit, Michigan.
Habermehl C; Biostatistics, the healthcare business of Merck KGaA, Darmstadt, Germany.
Bödding M; Clinical Pharmacology, the healthcare business of Merck KGaA, Darmstadt, Germany.
Rohdich F; Pharmacokinetics, the healthcare business of Merck KGaA, Darmstadt, Germany.
Lignet F; Pharmacokinetics, the healthcare business of Merck KGaA, Darmstadt, Germany.
Duecker K; Clinical Biomarkers, the healthcare business of Merck KGaA, Darmstadt, Germany.
Karpenko O; Safety Strategy, Olexacon Ltd., London, United Kingdom.
Pudelko L; Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany.
Gimmi C; Clinical Development, the healthcare business of Merck KGaA, Darmstadt, Germany.
LoRusso P; Medical Oncology, Yale University, New Haven, Connecticut.

Cancer Res Commun ; 3(8): 1638-1647, 2023 08.

Article in En | MEDLINE | ID: mdl-37637935

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Neoplasms Type of study: Clinical_trials Limits: Humans Language: En Journal: Cancer Res Commun Year: 2023 Document type: Article Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google